Scott Coleman
Corporate Officer/Principal bei XILIO THERAPEUTICS, INC.
Aktive Positionen von Scott Coleman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2022 | - |
Karriereverlauf von Scott Coleman
Ehemalige bekannte Positionen von Scott Coleman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - | - |
Ausbildung von Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Scott Coleman
- Erfahrung
